Frontotemporal Dementia

Changes in MAPT, the gene for the tau protein, cause an inherited form of frontotemporal dementia with parkinsonism. Using cryo electron microscopy, researchers determined the precise three dimensional shape of the tau filaments that build up in the brains of people carrying four different MAPT changes. Some produced the same fold seen in Pick's disease. Knowing the exact structure matters because scans and drugs that target tau have to recognize a particular shape, and different folds may need different tools.

Frontotemporal dementia and ALS sit on a spectrum, and the striatum, a deep brain region involved in movement and motivation, has been little studied in either. Researchers grew striatal nerve cells from the stem cells of people carrying the C9ORF72 expansion, comparing them with genetically corrected versions of the same cells. The patient cells showed faulty electrical behavior traced to potassium channels and to the segment of the cell where signals are triggered, identifying a specific target.

This study looked at three things together in people with inherited frontotemporal lobar degeneration: the brain's waste clearance system, a blood marker of nerve fiber damage called neurofilament light, and subtle changes in the structure of the cortex. All three were disturbed, and together they helped explain the decline in thinking that patients experienced. Because a blood test is far easier than a scan, findings like this support developing simple measures for tracking the disease and testing treatments.

As genetic testing becomes routine for frontotemporal dementia and ALS, families need honest information about what a positive result means. This paper explains that most disease causing variants, including the C9orf72 expansion, show reduced penetrance: carrying the change does not guarantee developing the illness, and published estimates vary widely. The authors discuss what that uncertainty means for counseling people tested before symptoms appear, and for deciding who should be offered treatments as they become available.

Inherited frontotemporal degeneration caused by MAPT gene mutations all ends in tau protein buildup, but different mutations may damage the brain in distinct ways. Examining brains from families carrying the V337M, P301L, or L284L mutations, researchers found each produced its own signature: V337M mainly affected neurons, P301L prominently involved star-shaped astrocytes, and L284L struck myelin-making oligodendrocytes. These patterns were consistent within families. Recognizing mutation-specific fingerprints deepens understanding of how each genetic form progresses and could help match patients to targeted future therapies.

Scientists still don't fully understand why brain cells die in genetic frontotemporal dementia. Using single-cell genome sequencing of 469 individual neurons, including from people with C9ORF72-linked FTD, this study found that affected neurons accumulate more DNA damage than healthy ones, following a distinctive pattern that points to oxidative stress. The damage was especially common in FTD neurons. Identifying a shared, gene-linked mechanism of neuronal injury across FTD and related diseases opens potential new directions for protecting brain cells.

How often does frontotemporal degeneration have an identifiable genetic cause, and who should be tested? A French laboratory analyzed 2,747 patients using a stepwise strategy: a progranulin blood test (flagging GRN), then testing for the C9orf72 repeat expansion, then sequencing 14 further genes. Overall, 12% had a genetic diagnosis, with GRN and C9orf72 accounting for over 80% of them. Family history was by far the strongest predictor, raising the yield four to fivefold. The study offers practical guidance for efficient, cost-effective genetic testing in this disease.

Weight and body composition often change in frontotemporal dementia, but nobody had checked whether this begins before symptoms. Researchers scanned 16 people carrying the C9orf72 expansion who were still well, on average 11 to 12 years before expected onset, alongside 28 relatives without the change. Carriers already showed differences in body composition, and these were linked to the hypothalamus and thalamus, brain regions that regulate appetite and metabolism. Changes this early could serve as a measure in prevention trials.

Trials aiming to slow or prevent genetic frontotemporal dementia need blood tests that show what the disease is doing. This study measured a panel of brain related proteins in the blood of 67 people carrying GRN or C9orf72 changes, 21 of them still without symptoms, and compared them with 42 relatives who do not carry the changes. Several proteins tracked with how advanced the illness was, which is what a trial needs to see whether a drug is working.

Most genetic frontotemporal dementia is caused by changes in three well-known genes (C9orf72, GRN, or MAPT), but some patients test negative for all three. This report describes a man with behavioral-variant FTD whose standard genetic tests were negative; broader sequencing then found a variant in NEK1, a gene better known in ALS. Whether NEK1 truly causes isolated FTD is still uncertain, but cases like this gradually expand the list of genes that may contribute to inherited frontotemporal dementia.

A repeat expansion in the C9orf72 gene is the most common genetic cause of frontotemporal dementia, but it is unclear what "intermediate-length" expansions, shorter than the classic disease-causing ones, actually do. Studying skin cells from carriers, researchers found long expansions produced the expected disease-related changes, while intermediate expansions altered energy metabolism without obvious cellular damage. The work helps clarify which C9orf72 expansion sizes are harmful, important for interpreting genetic test results and counseling families.

TMEM106B is a gene that influences a person's risk of frontotemporal lobar degeneration. Drawing on two large frontotemporal dementia cohorts (UCSF and the ALLFTD study), researchers measured the TMEM106B protein in spinal fluid and looked for links to patients' clinical features in both inherited and non-inherited disease. Connecting this genetic risk factor to a measurable protein and to symptoms could help with diagnosis, predicting the course of illness, and identifying who might benefit from future TMEM106B-directed treatments.

Mutations in the MAPT gene, which makes the tau protein, can directly cause inherited frontotemporal dementia (FTLD-tau). To study this, researchers built an improved, lower-cost mouse model carrying the human disease-causing P301L MAPT mutation that reliably develops tau pathology and memory problems. Cleaner, more accessible animal models like this make it easier for laboratories worldwide to investigate how MAPT mutations damage the brain and to test potential tau-targeting treatments.

The C9orf72 repeat expansion is the most common genetic cause of frontotemporal dementia and ALS. This review explains how the expansion harms brain cells in two ways, toxic "dipeptide repeat" proteins it produces, and loss of the gene's normal function in microglia (the brain's immune cells), which impairs their clean-up and immune roles. It also surveys how these mechanisms could become biomarkers or treatment targets, framing where C9orf72-directed therapy research is headed.

A repeat expansion in the C9orf72 gene is the most common inherited cause of frontotemporal dementia and ALS, and good animal models are needed to test therapies. Researchers delivered the disease-causing genetic repeats into mice and tracked the results, reproducing hallmark ALS/FTD features and teasing apart the two ways the mutation may cause harm, too much of a toxic product versus too little of the normal gene. Models like this give scientists a clearer testing ground for future C9orf72-targeted treatments.

A C9orf72 gene repeat expansion is a common cause of inherited frontotemporal dementia, but no brain scan has reliably flagged carriers. This Finnish study analyzed MRI scans of 56 FTD patients and found that shrinkage of a specific frontal-lobe region (the orbital gyri, especially on the right) distinguished C9orf72 carriers from those with sporadic disease with high accuracy. If confirmed, such an imaging clue could help doctors decide who to test genetically and better understand how this genetic form damages the brain.

Dominant changes in the progranulin gene cause frontotemporal lobar degeneration. Growing small three dimensional pieces of human brain tissue from stem cells carrying these changes, researchers found that astrocytes, the brain's support cells, became activated too early, which stressed nerve cells and led to loss of connections. TGF beta signalling drove the process. Because the problem starts in the support cells rather than the nerve cells themselves, calming that signal is a possible treatment approach.

Beyond the emotional impact of predictive testing, does simply knowing one's genetic status change how inherited frontotemporal dementia unfolds? This Dutch study of 228 people from FTD families compared those aware and unaware of whether they carry a pathogenic variant. Among carriers, awareness was associated with faster declines in verbal learning, recall, and word fluency over time; non-carriers who learned their status initially felt relief. The nuanced findings inform how genetic results are shared and followed up, an increasingly important consideration as predictive testing becomes more common.

Brain changes in frontotemporal dementia begin decades before symptoms. This study measured the volume and thickness of grey matter across the brain in 892 people, including carriers of all three main genetic causes, both before and after symptoms started. The result is a set of detailed maps showing how each gene's pattern of damage develops over time. As treatment trials begin, measures like these are what allow researchers to see whether a drug is slowing the underlying process.

There is growing evidence that carrying a frontotemporal dementia gene may affect brain development long before any degeneration begins. This preprint followed young adults carrying such changes over time, comparing brain volumes, executive thinking skills and blood markers against relatives without the changes. Tracking the same people repeatedly is more sensitive than comparing groups once, and helps separate lifelong differences from the start of disease. The work has not yet been peer reviewed.

Nearly all frontotemporal dementia causing progranulin changes work by leaving a person with too little of the protein, but how that leads to the TDP-43 clumps found in the brain is unclear. Researchers crossed progranulin deficient mice with mice carrying human TDP-43 and found that low progranulin made the TDP-43 related problems worse. Linking the two proteins in a living animal helps explain the sequence of events and gives a model for testing treatments.

Nerve cells move cargo along their long fibers, and this study used live imaging in mouse brain to watch that transport in animals carrying disease causing MAPT tau changes. Transport problems appeared early, before tangles formed and before any nerve cells died. Blocking an enzyme called p38 alpha reversed them. That the deficits could be undone suggests this early stage is not permanent damage, and points to a treatment window before irreversible loss.

Atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions is a young-onset form of frontotemporal dementia that usually appears sporadic. Scanning the genomes of pathologically confirmed cases, researchers found a strong risk signal on chromosome 15 and, using long-read sequencing, traced it to an expanded stretch of repeated DNA inside the GOLGA8A gene. Longer repeats made of a particular two-letter motif were strongly linked to the disease and were present in nearly 60% of cases. Although its exact effect is still unknown, the repeat appears to play a fundamental role in this condition.